Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Emergent BioSolutions Inc. (EBS) Investigation
NEW YORK, NY / ACCESSWIRE / April 5, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Emergent BioSolutions Inc. ("Emergent" or "the Company") (NYSE:EBS). Investors who purchased Emergent securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/ebs.
The investigation concerns whether Emergent and certain of its officers and/or directors have violated federal securities laws.
On March 31, 2021, the New York Times published an article reporting on the accidental contamination at an Emergent manufacturing plant in Baltimore of coronavirus vaccines developed by Johnson & Johnson and AstraZeneca PLC. According to reporting by the Associated Press, the Emergent factory where the contamination occurred had a series of lapses observed by the U.S. Food and Drug Administration in April 2020. On this news, Emergent's stock price fell $12.45 per share, or 13.4%, to close at $80.46 per share on April 1, 2021.
If you are aware of any facts relating to this investigation, or purchased Emergent shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/ebs. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
SOURCE: Bronstein, Gewirtz and Grossman, LLC
View source version on accesswire.com:
https://www.accesswire.com/638921/Bronstein-Gewirtz-Grossman-LLC-Notifies-Investors-of-Emergent-BioSolutions-Inc-EBS-Investigation
